FDA clears tiny surgical robot to remove bladder tumors
The FDA-authorized Virtuoso Endoscopy System uses needle-sized robotic arms to remove bladder tumors intact, helping pathologists assess detrusor muscle.
If a doctor finds a tumor in your bladder, you want to know what you're dealing with. Is it cancer? Has it reached the bladder muscle? The tissue removed during surgery helps answer those questions. Now, a tiny surgical robot could give doctors a clearer view of what's happening inside the bladder.
The FDA has authorized the Virtuoso Endoscopy System, developed by Nashville-based Virtuoso Surgical. It uses two needle-sized robotic arms to remove bladder lesions through the urethra, without cutting through the skin. The technology allows surgeons to remove many tumors in one piece, potentially giving pathologists better tissue samples to examine. This new approach to robotic bladder tumor removal could help doctors make more informed treatment decisions.
Missed CyberGuy LIVE? Watch the replay and discover 5 ways to travel smarter and save money.
Our free CyberGuy LIVE class, 5 Ways to Travel Smarter and Save Money, has ended, but you can still watch the full replay. Kurt "CyberGuy" Knutsson walks you through five practical ways to protect your phone and personal information, avoid common travel scams, find better deals, save money on bookings and use technology to make your travels easier and less stressful. No technical experience is needed.
Watch the free replay + downloadable checklist now at CyberGuyLive.com.
WOULD YOU TRUST A TINY DENTAL ROBOT?
The Virtuoso Endoscopy System uses a narrow medical instrument called a rigid endoscope, which enters the bladder through the urethra. At the tip are two miniature robotic arms made from a flexible metal alloy called nitinol. A surgeon controls both arms from a console. One arm lifts and holds the tumor while the other carefully separates it from the tissue underneath. This gives the surgeon two-handed control inside a very small space.
The technique is called en bloc resection, which means removing a tumor in one piece. Surgeons can already perform this procedure using conventional instruments, but it can be technically demanding. Virtuoso designed its system to make that approach easier to perform. The robot also relies entirely on the surgeon's movements. Unlike some autonomous surgical robots being tested in research settings, Virtuoso does not make surgical decisions or operate independently.
Bladder cancer affects thousands of Americans every year. The American Cancer Society estimates that approximately 84,530 people in the United States will receive a bladder cancer diagnosis in 2026. One of the most common procedures for evaluating and removing bladder tumors is called transurethral resection of bladder tumor, or TURBT. During conventional TURBT, surgeons often remove tumors in smaller fragments. While effective for many patients, that approach can disrupt the tissue's original structure. As a result, pathologists may have a harder time determining how deeply cancer has grown. That's particularly important when it comes to the bladder's muscle layer, called the detrusor muscle. Doctors need to know whether cancer has reached this muscle because that can change the recommended treatment.
Removing a lesion intact may preserve more of the information pathologists need. It can also allow them to examine the tissue around the tumor more clearly. Dr. Duke Herrell, a urologic surgeon and CEO of Virtuoso Surgical, explained the potential benefit in the company's FDA announcement. "Removing a tumor intact can provide a better tissue specimen, which supports clearer diagnosis and staging," Herrell said. For patients, a more complete tissue sample could help their medical team determine the next steps with greater confidence.
Virtuoso has already tested the system in human patients, and the early clinical findings are encouraging. In the first 20 patients enrolled in the company-sponsored VIABLE study at The Chinese University of Hong Kong, 94% of removed lesions contained detrusor muscle. That exceeded the study's predefined performance goal of 60%. Researchers also reported that surgical margins could be evaluated in 93% of malignant lesions. Surgical margins are the edges of the removed tissue. Examining them can help doctors assess whether cancer cells extend to the edge of the sample. However, being able to evaluate a margin does not necessarily mean it is free of cancer. The company reported no adverse events during the operations.
There are important limitations to these findings. The study involved a small number of patients at one medical center. The previously published first phase of the same VIABLE study involved six patients and recorded two postoperative adverse events. One patient experienced temporary urinary retention, while another developed a chest infection later linked to a separate esophageal tumor. The company also compared its results with previously published research on conventional bladder tumor removal.
However, the Virtuoso study did not directly compare the robot against traditional instruments in a randomized trial. Researchers still need larger studies to determine whether the system improves long-term outcomes or reduces the need for additional procedures.
BRAIN TUMOR FOUND DURING PREVENTIVE SCAN PUTS FULL-BODY MRIS BACK IN THE SPOTLIGHT
The FDA granted De Novo authorization for the Virtuoso Endoscopy System on Oct. 30, 2026. The company publicly announced the decision on Nov. 10. The authorization establishes a new FDA classification for robotic surgical instruments that operate through an endoscope inside the body. Specifically, the system is authorized to remove bladder lesions in adult patients and obtain tissue samples, including bladder muscle, to assist in diagnosing bladder cancer.
The decision follows the FDA's September 2025 Breakthrough Device Designation for the system. That earlier designation recognized the technology's potential and allowed the company to receive additional regulatory guidance during development. However, the new authorization does not establish that the robot improves survival rates or prevents cancer from returning. The system must also be operated by trained surgeons in an operating room.
Virtuoso Surgical plans a limited U.S. launch in 2027, starting with leading urology centers. The company has not announced which hospitals will receive the system first. That means patients may have to wait before the technology becomes available at their local hospital. Questions also remain about pricing and insurance coverage.
Virtuoso is exploring other potential applications for its miniature robotic instruments, including procedures involving the lungs. However, those uses remain experimental and have not received FDA authorization. For now, the company's focus is bladder surgery, where better tissue samples could help doctors evaluate cancer more accurately.
If you or someone you love is facing bladder cancer, this technology could eventually provide another surgical option. Its miniature robotic arms may help doctors obtain more complete tissue samples during the initial procedure. However, availability will be limited at first, and the early results still need confirmation in larger studies. The robot's FDA authorization also does not guarantee better results for every patient.
If you're discussing bladder tumor surgery with a urologist, ask whether en bloc resection might be appropriate for your situation. You should also ask how the surgeon plans to obtain enough tissue to determine whether cancer has reached the bladder muscle. Those answers can help you understand your options before surgery.
When you're facing a possible cancer diagnosis, getting accurate answers as early as possible can make a real difference. That's what I like about this technology. Virtuoso's tiny robotic arms could help surgeons collect better tissue samples without taking control away from the medical professional performing the operation. It's also encouraging to see the FDA authorize a system designed for such a specific surgical challenge. Still, 20 patients represent a very small study, and I want to see how this robot performs in larger trials before getting too excited about its potential. If the results hold up, this could become a valuable addition to the tools doctors use to diagnose bladder cancer.
Would you trust a surgeon using this new robotic system to remove a tumor, or would you prefer a conventional procedure until there's more evidence of its benefits? Let us know by writing to us at Cyberguy.com
Sign up for my FREE CyberGuy Newsletter
Copyright 2026 CyberGuy.com. All rights reserved.